Testing a low-cost mobile colposcope for cervical precancer detection
Tests a low-cost imaging device to detect cervical precancer in women aged 25 and older.
Plain-language title generated from the registry record
Registry title: Low-cost Imaging Technology for Global Prevention of Cervical Cancer
Key facts
- Where
- Barretos and Porto Alegre, BrazilSee the 2 sites
Where in Brazil
- Barretos Cancer HospitalBarretos, BrazilTaking people
- Irmandade Santa Casa de Misericordia de Porto AlegrePorto Alegre, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Barretos Cancer Hospital
- Trial code
- NCT05078528
- Record updated
- 6 February 2025
- Original description
Cervical cancer remains the first or second leading cause of cancer death among women in many low-and middle-income countries. Cervical cancer prevention programs in low-resource settings are hampered by a lack of personnel with appropriate clinical expertise, lack of pathology services, and lack of associated infrastructure. There is an urgent need for appropriate diagnostic tools to enable accurate screening and diagnosis in low-resource settings. The purpose of this study is to develop and validate a low-cost Multimodal Mobile Colposcope (MMC) for global cervical cancer prevention programs. This new device will combine the imaging capabilities of a mobile colposcope with the microscopic imaging capabilities of a fiber-optic confocal imaging probe.Read full original descriptionShow less
Low-cost Mobile Colposcopy and Confocal Imaging for Global Prevention of Cervical Cancer
Cervical cancer remains the first or second leading cause of cancer death among women in many low-and middle-income countries. Cervical cancer prevention programs in low-resource settings are hampered by a lack of personnel with appropriate clinical expertise, lack of pathology services, and lack of associated infrastructure. There is an urgent need for appropriate diagnostic tools to enable accurate screening and diagnosis in low-resource settings. The purpose of this study is to develop and validate a low-cost Multimodal Mobile Colposcope (MMC) for global cervical cancer prevention programs. This new device will combine the imaging capabilities of a mobile colposcope with the microscopic imaging capabilities of a fiber-optic confocal imaging probe.
Inclusion: Women >25 years of age; Women undergoing colposcopy due to abnormal cervical screening or follow-up for a history of dysplasia; Women of childbearing potential must have a negative urine or blood pregnancy test; Ability to understand and willingness to provide informed consent by signing specific Informed Consent Document.
Exclusion: Women with known allergy to proflavine or acriflavine; Women under 25 years of age; Women who have undergone hysterectomy with removal of the cervix; Women who are pregnant or nursing at the time of enrollment; Incapacitated women or in vulnerable situations or who are not willing to give consent.